Carbazochrome

Research use only, not for human use.

Carbazochrome?is an antihemorrhagic, or hemostatic, agent that will cease blood flow by causing the aggregation and adhesion of platelets in the blood to form a platelet plug, ceasing blood flow from an open wound.

Carbazochrome?is an antihemorrhagic, or hemostatic, agent that will cease blood flow by causing the aggregation and adhesion of platelets in the blood to form a platelet plug, ceasing blood flow from an open wound. It is hoped that this drug can be used in the future for preventing excessive blood flow during surgical operations and the treatment of hemorrhoids, but research on its effectiveness and the severity of possible side effects remains to be fairly inconclusive.?Carbazochrome?has been investigated for use in the treatment of hemorrhoids in a mixture with?troxerutin.(In Vitro):Carbazochrome (0.1-10 μM) inhibits the Bradykinin induced and thrombin-induced formation of [3H]IP3 in a concentration-dependent manner. Carbazochrome (0.1-1 μM), when included from 30 min before stimulation, significantly suppressed the enhancement of permeability induced by vasoactive substances.(In Vivo):Carbazochrome inhibits the severe pulmonary dysfunction induced by the intravenous injection of radiographic contrast media. Carbazochrome (1-10 mg/kg, i.v.) attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats.

Carbazochrome (0.1-10 μM) inhibits the Bradykinin induced and thrombin-induced formation of [3H]IP3in a concentration-dependent manner.Carbazochrome (0.1-1 μM), when included from 30 min before stimulation, significantly suppressed the enhancement of permeability induced by vasoactive substances.

Carbazochrome inhibits the severe pulmonary dysfunction induced by the intravenous injection of radiographic contrast media. Carbazochrome (1-10 mg/kg, i.v.) attenuates pulmonary dysfunction induced by a radiographic contrast medium in rats. Animal Model:Male Sprague-Dawley rats weighing 180-230 g Dosage:10 mg/kg Administration:I.v.; injected 30, 60, or 90 min before Ioxaglate injection (4 g I/kg, i.v.).Result:Attenuated the Ioxaglate-increased vascular permeability at the dose of 1, 5 and 10 mg/kg in a dose-dependent manner, achieving statistical significance at 5 and 10 mg/kg.

Carbazochrome | AC-17 | AC 17 | AC17 | Adona

Others

Other Targets

myosin light-chain kinase| PLA2

——

——

69-81-8

236.23

C10H12N4O3

>98% (HPLC)

In Vitro:?H2O : 5 mg/mL (21.17 mM)

OC1C2=C/C(=N/NC(=O)N)/C(=O)C=C2N(C1)C

(Z)-2-(3-hydroxy-1-methyl-6-oxo-1,2,3,6-tetrahydro-5H-indol-5-ylidene)hydrazine-1-carboxamide

(-20℃)

With Ice Pack

≥ 2 years